Hantz Financial Services, Inc. Vir Biotechnology, Inc. Transaction History
Hantz Financial Services, Inc.
- $6.19 Billion
- Q2 2025
A detailed history of Hantz Financial Services, Inc. transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 1,256 shares of VIR stock, worth $7,598. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,256
Previous 21
5880.95%
Holding current value
$7,598
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding VIR
# of Institutions
242Shares Held
109MCall Options Held
342KPut Options Held
150K-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$101 Million0.67% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$99.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.2MShares$80 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL12.9MShares$78.1 Million34.47% of portfolio
-
State Street Corp Boston, MA5.25MShares$31.8 Million0.0% of portfolio
About Vir Biotechnology, Inc.
- Ticker VIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 132,638,000
- Market Cap $802M
- Description
- Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...